C difficile risk
Oral Bioavailability


Loading dose (3.375-4.5 g) over 30 min x 1

  • Osteo, CF: 3.375 g q6h IV over 4-hr – OR – 4.5 g q8h IV over 4-hr

  • All other indications: 3.375 g q8h IV over 4-hr

CrCl 0 - 20CrCl > 203.375 g q12h IV over 4-hr – OR – 4.5 g q12h IV over 4-hrUsual dosing

3.375 g q12h IV over 4-hr – OR – 4.5 g q12h IV over 4-hr

3.375 g q8h IV over 4-hr

General Information

Broad spectrum agent with anti-pseudomonal activity.

Used for severe infections including:

  •  Pneumonia

  •  Intra-abdominal/hepatobiliary

  •  UTI

  •  Polymicrobial skin and soft tissue infection

  •  Febrile neutropenia

  • Allergy/rash (immediate or delayed)

  • Cytopenias- esp. thrombocytopenia

  • Eosinophilia

  • Interstitial nephritis

  • Abnormal liver enzymes

May increase levels of methotrexate Increased risk of nephrotoxicity via synergism with vancomycin

Antimicrobial class: Ureidopenicillin with a beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Poor

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.